{"schema_version":"secwatch.filing_event.v1","accession":"0001384101-21-000173","form_type":"8-K","ticker":"VCYT","cik":"0001384101","company_name":"VERACYTE, INC.","filed_at":"2021-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.310685+00:00","generated_at":"2026-06-28T10:34:10.090619+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Veracyte Q3 2021 revenue $60.4M (+94% YoY); raises FY guidance to $210-218M","bullets":["Total revenue $60.4M, up 94% YoY; volume 20,972 tests (+79%).","Net loss $14.1M ($0.20 EPS) vs $4.1M loss Q3 2020; includes HalioDx costs.","Completed HalioDx acquisition for $321M; launched Percepta Nasal Swab and Decipher Bladder tests.","FY 2021 revenue guidance raised to $210-218M from $200-208M, implying 79-86% growth.","Cash $164M at quarter-end; operating cash used $1.4M incl. $3.9M acquisition expenses."],"urls":{"canonical":"https://secwatch.observer/filing/0001384101-21-000173","json":"https://secwatch.observer/filing/0001384101-21-000173.json","markdown":"https://secwatch.observer/filing/0001384101-21-000173.md","text":"https://secwatch.observer/filing/0001384101-21-000173.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1384101/000138410121000173/0001384101-21-000173-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1384101/000138410121000173/vcyt-20211109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:34:10.090619+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}